1 TITLE PAGE

- 3 Diagnostic test accuracy in longitudinal study settings: Theoretical approaches with use cases
- 4 from clinical practice
- 5

- ^c 25 Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany
- 26 d Research Group Bioinformatics, Fraunhofer Institute for Toxicology and Experimental
- 27 Medicine, Hannover, Germany
- 28 ^e medisite GmbH, Hannover, Germany
- 29 f Big Data in Medicine, Department of Health Services Research, School of Medicine and
- 30 Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany
- 31 * These authors contributed equally to this work.
- 32

33 ORCiD of all authors

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.08.04.23293637;](https://doi.org/10.1101/2023.08.04.23293637) this version posted August 8, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted m

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

35 Full name, postal address, e-mail and telephone number of the corresponding authors

- 36 Julia Böhnke, MSc
- 37 Institute of Epidemiology and Social Medicine
- 38 University of Münster
- 39 Albert-Schweitzer-Campus 1
- 40 48149 Münster
- 41 Germany
- 42 Phone: +49 251 83 57033
- 43 Fax: +49 251 83 55300
- 44 Mail: boehnkej@uni-muenster.de
- 45 ORCID: 0000-0003-1249-4581
- 46

47 Word count

- 48 199 of 200 words in Abstract
- 49 3,942 of 4,000 words in main article (excludes the title page, abstract, table(s), acknowledgments,
- 50 contributions and references)
- 51
- 52 Article type
- 53 Practice of Epidemiology and Methodology

54 ABSTRACT

55 In this study we evaluate how to estimate diagnostic test accuracy (DTA) correctly in the presence 56 of longitudinal patient data (i.e., repeated test applications per patient). We used a nonparametric 57 approach to estimate sensitivity and specificity of diagnostic tests for three use cases with different 58 characteristics (i.e., episode length and intervals between episodes): 1) systemic inflammatory 59 response syndrome, 2) depression, and 3) epilepsy. DTA was estimated on the levels 'time', 60 'event', and 'patient-time' for each diagnosis, representing different research questions. A 61 comparison of DTA for these levels per and across use cases showed variations in the estimates, 62 which resulted from the used level, the time unit (i.e., per minute/hour/day), the resulting number 63 of observations per patient, and the diagnosis-specific characteristics. Researchers need to 64 predefine their choices (i.e., estimation levels and time units) based on their individual research 65 aims, including the estimand definitions, and give an appropriate rationale considering the 66 diagnosis-specific characteristics of the target outcomes and the number of observations per patient 67 to make sure that unbiased and clinically relevant measures are communicated. Nonetheless, 68 researchers could report the DTA of the test using more than one estimation level and/or time unit 69 if this still complies with the research aim.

70

71 KEYWORDS

72 Diagnostic study, diagnostic test accuracy, longitudinal study, data cluster, nonparametric method,

73 estimation level

74 1. INTRODUCTION

75 A diagnostic test (DT) can be any device (e.g., biomarker quantification of bodily fluids, magnetic 76 resonance imaging, or clinical decision support system $[CDSS]$ ¹⁻³ with which healthcare 77 professionals can classify a target condition (e.g., diseased vs disease-free)^{1–6} and make an 78 informed decision based on the test's result. Each test requires to be assessed for its diagnostic 79 accuracy (i.e., sensitivity and specificity) before its usage in daily practice within medical settings⁷. 80 Ideally, a DT should provide a correct classification of the target condition (i.e., *true positives* [TP], 81 *true negatives* [TN], Appendix 1) while being safe and effective in its diagnostic performance^{2,3,5}; 82 thus, the quantity of *false positive* (FP) and *false negative* (FN) test results should be minimal⁵. Misdiagnoses can have serious consequences for the patient's health^{2,5}, including mental distress⁷, 84 and/or for a country's healthcare system (e.g., unnecessary costs)².

85

86 The diagnostic validity of the DT (referred to as index test, IT) is best assessed in a diagnostic test 87 accuracy (DTA) study using an established, carefully selected reference standard (RS) as the 88 . ground truth^{5,7}. To minimize potential influences, both tests should be blinded to each other, and 89 performed without time delay to avoid diagnostic differences caused by temporal changes in the 90 target condition^{2,5}. Conducting the evaluation of a DT with a DTA study provides healthcare 91 professionals with the necessary information on the DT's performance so that they can make an 92 informed decision⁵. Information on test performance is usually reported in terms of sensitivity and 93 specificity (Appendix 1 for key terminology of DTA studies).

94

95 Lately, researchers showed that many DTA studies are of low quality, do not necessarily represent 96 the clinical situation of interest, and/or are associated with a considerable risk of bias^{8,9}. As a 97 consequence, the DT under review might not be used in practice, or the research may be

120 Note that other methods of DTA estimation accounting for longitudinal data¹⁰ are available (not 121 addressed in this paper); regardless, the approaches of this article (choice of time unit and 122 estimation level) apply.

123

124 2. METHODS

125 This study is reported in accordance with the items of the 2015 Standard for Reporting Diagnostic 126 Accuracy guideline²⁰ (Appendix 3). In the following, we use the following nomenclature: A "time" 127 unit" is chosen by the researcher, i.e. the diagnostic status is assessed every minute/hour/day etc. 128 A "time point" refers to a specific minute/hour/day within the longitudinal setting, e.g. hour 24 of 129 a patient's stay. A "block" is an aggregation of labeled time points based on the rules explained 130 below.

131

132 2.1 DTA estimation levels

133 We present three DTA estimation levels (Figure 1 and Appendix 4) determining an IT's

134 performance using longitudinal patient data.

135

137 Figure 1: Visualization of the data structure and its subunits that are included in the diagnostic test 138 accuracy estimation. Two options for the event-level are presented that differ regarding their 139 groupings of labeled time points into blocks.

140

136

141 2.1.1 Time-level

142 The time-level provides labels (i.e., TP, TN, FP, or FN) for every time point. This level's estimand 143 is the diagnostic status per time point without any aggregation.

144

145 2.1.2 Event-level

146 The event-level aggregates consecutive, labeled time points based on diagnostic status; thus, per

147 patient, the minimum block length is one time unit and the maximum block length is equivalent to

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.08.04.23293637;](https://doi.org/10.1101/2023.08.04.23293637) this version posted August 8, 2023. The copyright holder for this

148 the total of all time points (i.e., no change in diagnostic status). This level requires that the estimand 149 is a change in the diagnostic status.

150 In the following, we differentiate between blocks based on the RS alone, or on both, the IT and the 151 RS.

152 2.1.2.1 Blocks based on RS

153 The time point where the RS changes its diagnostic status determines the end of the previous block 154 and the start of the new block. With this definition, the result of the RS is assumed to be known 155 while the result of the IT is a random variable that follows a Bernoulli distribution.

156 For DTA estimation, the time point labels per block are summarized into one single label. FP and 157 FN labels always overrule TP and TN labels as they indicate differences between the tests. The 158 summarized block labels are used in the DTA estimation. This labeling penalizes any differences 159 (i.e., early/late episode start/end, etc.) between the DTs by having an increase of FP and FN labels. 160 We can control for this by applying modifying rules, for example with applying a clinician-based 161 tolerance margin rule so that if the IT starts/ends within the tolerance margin of the RS, the IT's 162 diagnostic status of the specific time points is changed in accordance with the RS's diagnostic 163 status (i.e., no "punishment" if IT starts/ends too early/late). However, if the IT starts/ends outside 164 of the tolerance margin, the IT's diagnostic status of these specific time points remains unchanged. 165 A %-correctness rule can also be applied according to which the IT's diagnostic status per patient 166 is corrected in accordance with the RS's diagnostic status if at minimum $P_{diseased}$ percent of single 167 time points per a diseased block and at minimum $P_{disease-free}$ percent of single time points per a 168 disease-free block are correctly classified. The P's are diagnosis-specific. For our analysis, we used 169 a \pm 1 time interval tolerance margin around the RS's episode start and end and an 85% correction 170 rule for diseased and disease-free blocks (see Appendix 5 for analyses using other modifying rules). 171 Afterwards, the labels are summarized into a single label and used for the DTA estimation.

172 2.1.2.2 Blocks based on IT and RS

173 At first, each time point is labeled and then all consecutive time points with an identical label are 174 grouped together into blocks. Each new block starts and ends with a change of the diagnostic status 175 of the IT and/or the RS. Afterwards, each block is given a single summary label that is used for the 176 DTA estimation. Modifying rules can be applied. With this definition, both the result of the RS and 177 the results of the IT are random variables, which violates one assumption of our proposed 178 nonparametric approach.

- 179
- 180 2.1.3 Patient-time-level

181 The patient-time-level summarizes the occurrence of all labels per patient during the defined 182 period; thus, a patient adds at minimum one label (i.e., either TP, FP, FN, or TN) or at maximum 183 all four labels once to the DTA estimation. This level's estimand is the occurrence of the different 184 possible labels, without considering their respective frequency. It is not suited for usage because 185 with time the probability of observing all four labels increases; hence, this level, at best, is a biased 186 estimate of 50% sensitivity and 50% specificity.

187

188 2.1.4 Example of labeling per estimation level

189 An example of labeling of the three levels is displayed in Figure 2. Each crossed out cell marks the 190 presence of the target condition according to the respective test at that particular time point. Below 191 are the labeled units per level, as described previously, which are used for the DTA estimation. The 192 event-level with blocks based on IT and RS as well as the patient-time-level are shown for 193 illustration only; they should not be used in clinical practice.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.08.04.23293637;](https://doi.org/10.1101/2023.08.04.23293637) this version posted August 8, 2023. The copyright holder for this

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Diagnostic test accuracy labeling using the various estimation levels. Each label per estimation level is included in the diagnostic test accuracy estimation. Time-level: Each individual time point is labeled by comparing the reference standard diagnostic status to the index test diagnostic status.

Event-level (blocks based on reference standard). The time points where the reference standard changes its diagnostic status determined the end of the previous block and the start of the new block; thus, the result of the reference standard is assumed to be not influenced by chance while the result of the index test is a random variable that follows a Bernoulli distribution. For the unmodified version, the ind at time points 10-11 of the index test) per block (here: diseased and disease-free blocks) is applied according to which the index test is modified. Afterwards, the labeled time points per block are summarized to one single label.

Event level (blocks based on index test and reference standard): All labeled, consecutive time points with an identical diagnostic label are group together into blocks. Each new block starts and ends with a change of the d since it violates one assumption of our proposed nonparametric approach! • Patient-time-level: Each single occurrence of a label is only once included in the diagnostic test accuracy estimation; hence, the frequency of labels is ignored. ATTENTION: This level is not suited for usage because wit

196 Figure 2: Example of labeling on the three levels. The time-level adds 18 true positive (TP), 3 false 197 positive (FP), 2 false negative (FN), and 2 true negative (TN) observations to the DTA estimation. 198 The DTA estimation of the event-level using blocks based on RS adds 1 TP, 1 FP, and 1 TN to the 199 DTA estimation while the event level using blocks based on both tests adds 2 TP, 2 FP, 1 FN, and 200 2 TN observations. On the patient-time-level, all four labels were observed; thus, this patient adds 201 one observation to each label.

202

203 2.2 The nonparametric approach

204 The DTA can be estimated using the nonparametric approach based on research by Konietschke $\&$ 205 Brunner¹⁹ and Lange¹¹ which is robust and reliable even when accounting for intra- and interclass 206 correlations²¹. Konietschke & Brunner^{19,21} proposed a categorization of participants into three 207 cluster groups, regardless of the individual participant's number of repeated measurements:

- 211 'Present' (ic_1) : incomplete cases with target condition consistently present (i.e., patient was 212 consistently diseased during the total observation period; these cases are "incomplete" 213 because disease-free phases are missing).
- 214 'Mix' (c) : complete cases with target condition both present and absent (i.e., the patient 215 experienced diseased and disease-free phases during the total observation period).

216 In the DTA estimation, this method uses a unified nonparametric model to estimate the area under 217 the curve, sensitivity, and specificity accounting for a longitudinal data format $11,22$. This approach 218 applies a nonparametric rank statistic while accounting for the clustering by using the weighted 219 estimation strategy (i.e., weighting by size of the clusters; thus, larger clusters have larger weights 220 than smaller ones)^{11,21}. This allows assigning an equal weight to all subunits of the same cluster²¹. 221 Each DTA estimate is presented with its 95% logit Wald confidence interval (CI). For details on 222 the method, we refer to $11,19$. The R code for the analyses is provided at https://zivgitlab.uni-223 muenster.de/ruebsame/dta_longitudinal_data_methods.

224

225 2.3 The datasets

226 We used three publicly available datasets to show the application of our proposed methods across 227 different medical fields. Dataset descriptions, dataset labeling, and information on ITs and RSs are 228 presented in Appendix 5.

230 2.3.1 SIRS dataset

231 The SIRS dataset includes 168 male and female pediatric patients (0-17 years). All participants 232 were consecutively recruited at a single study center (i.e., Department of Pediatric Cardiology and 233 Pediatric Intensive Care at Hannover Medical School, Germany) between 2018-08-01 and 2019- 234 03-31. A total of 101 of the 168 patients developed at least one SIRS episode at any time during 235 their inpatient stay at the study center. For details, we refer to $23-25$. We used the data of 36 patients 236 (26 diseased individuals) to ensure comparability with the other datasets regarding the sample size.

- 237
-

238 2.3.2 Depression dataset

239 The depression dataset includes records of 55 adult patients of which 23 experienced a depressive 240 episode (5 inpatients and 18 outpatients) and 32 individuals did not (23 hospital employees, 5 241 students, and 4 former, currently non-depressive, patients). All individuals were recruited while 242 being treated at the Department of Psychiatry of the Haukeland University, Norway. The 243 depressive patients were equipped with a wearable sensor that recorded the patients' motor activity 244 per minute since depressive people tend to decrease their personal activity (i.e., reduced active 245 during day-time hours). In total, activity data from 693 days were recorded (diseased: 291 days; 246 controls: 402 days ²⁶. For this study's purpose, the dataset included all cases and only the first 10 247 controls (33 patients in total).

- 248
-

249 2.3.3 Epilepsy dataset

250 The epilepsy dataset entails electroencephalogram (EEG) recordings of 22 pediatric and young 251 adult patients (5 males, 3-22 years; 17 females, 1.5-19 years; ID chb01 and chb21 are from the 252 same person) with intractable seizures of the Boston Children's Hospital, USA. One extra patient 253 was added later. Each patient was likely to develop an epileptic episode due to having stopped the

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.08.04.23293637;](https://doi.org/10.1101/2023.08.04.23293637) this version posted August 8, 2023. The copyright holder for this

254 anti-seizure medication under medical supervision in an inpatient setting. A total of 197 episodes 255 were recorded (i.e., each patient had ≥2 episodes). EEG-signals were recorded at a frequency of 256 256 samples per second with 16-bit resolution²⁷. Modifications were applied to the dataset to meet 257 this study's research purpose: Six additional disease-free synthetic patient records were added to 258 have a sample size of 30 patients.

259

260 2.4 Analysis

261 The assessment of the datasets by the ITs and RSs (Appendix 4 and 5) was consistently applied to 262 the (modified) datasets. Missing values of the IT's and RS's assessments were not observed. 263 Indeterminate test results were not registered.

264 Sensitivities and specificities were estimated for each diagnosis per time unit (i.e., minute, hour, 265 and day) and per estimation level (i.e., time-level, event-level, and patient-time-level) using the 266 nonparametric approach^{11,19}. All analyses were conducted using R version 4.2.3 (2023-03-15)²⁸. 267 The DTA estimation package is accessible via https://github.com/wbr-p/diagacc.

268

269 3. RESULTS

270 3.1 Study participants

271 The SIRS, depression, and epilepsy datasets included 36 (10 disease-free individuals), 33 (10 272 disease-free individuals), and 30 participants (6 disease-free individuals), respectively. For details 273 on the participant's flow per diagnosis and demographic characteristics, see Appendix 6 and 7.

274

275 3.2 Test results per use case (intra-study evaluation)

276 We observed relevant differences within and across the different use cases for the three levels and

277 time units (Figure 3 and Table 1).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.08.04.23293637;](https://doi.org/10.1101/2023.08.04.23293637) this version posted August 8, 2023. The copyright holder for this

278

279 3.2.1 SIRS

280 The DTA evaluation for the different time units estimated sensitivities of 84.8-93.6% on the time-281 level, of 43.5-86.4% without modifying rules and 71.7-93.2% with modifying rules on the event-282 level with blocks based on RS, of 62.0-86.3% on the event-level with blocks based on IT and RS, 283 and of 58.0-82.9% on the patient-time-level. Specificities of 94.4-97.6% on the time-level, of 68.1- 284 82.5% on the event-level without modifying rules and 90.5-97.6% with modifying rules on the 285 event-level with blocks based on RS, of 75.4-83.7% with blocks based on IT and RS, and of 71.6- 286 81.1% on the patient-time-level were estimated.

287

288 3.2.2 Depression

289 The DTA assessment for the different time units estimated sensitivities and specificities that were 290 ranging from 93.6% to 93.9% and from 97.5% to 98.3% on the time-level, respectively. On the 291 event-level with blocks based on RS, the unmodified sensitivity was 79.3% for all time units and 292 the unmodified specificities ranged between 29.0-98.4%, while the modified DTA estimated an 293 86.2% sensitivity for all time units and specificities of 69.4-98.4%. The DTA of the event-level 294 with blocks based on IT and RS estimated sensitivities of 80.6% for all time units and specificities 295 of 58.9-98.4%. On the patient-time-level, the sensitivity was 78.6% irrespective of the used time 296 unit, while the specificities ranged between 60.0% and 97.1%.

297

298 3.2.3 Epilepsy

299 The use case epilepsy estimated sensitivity and specificity of 80.5-98.7% and 98.1-98.5% on the 300 time-level, respectively. Sensitivities of 73.4-96.9% and specificities of 67.3-96.0% were estimated 301 on the event-level with blocks based on RS without modifying rules, while sensitivities of 71.7-

302 93.2% and specificities of 90.5-97.6% were estimated on the event-level with blocks based on RS 303 after applying modifying rules. On the event-level with blocks based on IT and RS, DTA ranges 304 of 74.2-97.1% sensitivities and 76.6-96.0% specificities were estimated, while sensitivities and 305 specificities ranged between 55.8% and 96.0% and 58.8% and 95.0%, respectively, on the patient-306 time-level.

307

308 3.3 Test results across use cases (inter-study evaluation)

309 The evaluation across use cases showed that the highest DTAs, irrespective of used time unit and/or 310 diagnosis, were estimated on the time-level, while the DTA on the event-level and patient-time-311 level were lower. The event-level with blocks based on RS showed that the unmodified DTA 312 estimates were decreased compared to the DTA estimates after IT correction which sensitively 313 depend on the chosen tolerance margin and/or %-correction rule. Moreover, the DTA estimates 314 using 'days' as a time unit were closer to 100% than the DTA estimates using 'hours' or 'minutes' 315 as time units. The number of observations decreased dramatically from the time-level to the event-316 level and/or patient-time-level which is somewhat mirrored by the DTA estimates.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.08.04.23293637;](https://doi.org/10.1101/2023.08.04.23293637) this version posted August 8, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted m

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

319 Figure 3: Summary of the diagnostic test accuracy of all three diagnoses stratified by the diagnostic 320 test accuracy indices (i.e., sensitivity and specificity), by the estimation level (i.e., time-level, 321 event-level, and patient-time-level), and by the time unit (i.e., minute, hour, and day).

322 Table 1: Summary of the diagnostic test accuracy per diagnostic level (i.e., per time-level, per event-level, and per patient-time-level) per

323 time unit (i.e., per minute, per hour, and per day) for the diagnoses 'Systemic Inflammatory Response Syndrome' (SIRS), depression, and

324 epilepsy.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.08.04.23293637;](https://doi.org/10.1101/2023.08.04.23293637) this version posted August 8, 2023. The copyright holder for this

325 4. DISCUSSION

326 Our study shows that two features should be considered when presenting the DTA of an IT in the 327 case of repeated test application and longitudinal data. These are the estimation level and the time 328 unit which should always be chosen in accordance with diagnosis-specific characteristics and 329 possible changes in the number of patient-related observations per cluster. An inappropriate feature 330 in accordance with a specific research question and related estimand causes an increase in TP and 331 TN observations. The selected diagnosis-specific choices of the estimation level and time unit show 332 hereby a clear relation to the number of observations included in the DTA estimation. Because the 333 time-level includes every single time point, the DTA estimation may be enriched with TP and TN 334 observations. This is less problematic for the event-level that summarizes time points per diseased 335 and disease-free block into a single, block-specific label; thus, fewer labels are included in the DTA 336 estimation. This requires that the blocks are based on the diagnostic status of the RS so that the 337 length of the blocks is fixed (i.e., not subject to the random variable IT). Moreover, if the time unit 338 does not reflect well the diagnosis-specific characteristics, the DTA estimates may either have 339 increased precision when using a small unit (i.e., increase in observations), or be distorted due to 340 losing information as the unit was too large (e.g., epileptic seizures last only seconds to minutes 341 which excludes using 'days' as time unit). In the last case, possible differences between the tests 342 resulting in FN or FP labels may be lost. Estimand and statistical approach should be chosen 343 appropriately so that they account for the longitudinal data format, because each of these features 344 impacts the DTA estimation¹⁸. Using a simple approach not accounting for this specific data 345 structure leads to a considerable overestimation of DTA when compared with what is relevant for 346 clinical practice.

348 DTA can be reported using different levels. However, most studies reported their used analytical 349 procedures and reporting level²⁹ rather intransparently; only few provided details on the estimation 350 level and how it was constructed. For example, Wulff *et al.*²³ used the time-level (time unit: days) 351 and the patient-time-level to present their CDSS's performance. Bode *et al.*³⁰ formed blocks that 352 were labeled and the labels of the individual blocks were included in the DTA estimation (i.e., 353 event-level with blocks based on IT and RS). Generally, various estimation levels can be used for 354 the analysis and reporting of an IT's DTA, but researchers should carefully consider their research 355 objective(s), related estimand(s), and potential differences of interpretation between the estimation 356 levels, particularly in the context of longitudinal data. In the evaluation of longitudinal data, the 357 time-level is always a good technical starting point, since the event-levels and the patient-time-358 level are based on the labeling of every time point so that they can be derived from the time-level 359 DTA estimation. We recommend using the time-level when having a disease with short episodes 360 (e.g., epileptic seizures), when the IT aims to predict a disease, or if the aim is to assess the IT's 361 precision. The event-level with blocks based on RS can be used if the aim is to assess the IT's 362 performance in a clinical setting (i.e., here the focus is on the periods that have correctly or 363 incorrectly been classified by the IT) without having a constant decision to make (i.e., decision 364 only required when IT changes its diagnostic status). The event-level with blocks based on IT and 365 RS and patient-time-level are not suited for usage as discussed in the Methods. We recommend 366 reporting multiple DTA estimations of a test using various level and time unit combinations while 367 still considering related differences in interpretation.

368

369 The time unit, which was used for classifying a patient as either diseased or disease-free, also 370 influences DTA estimation because it affects the number of labeled observations in the clusters. 371 Many DTA studies do not provide sufficient information to identify if they used longitudinal data⁸

372 and/or their time unit. Studies that use longitudinal data should report their time unit and how they 373 account for the inflation of the type I error in DTA estimation³¹, which is caused by having repeated 374 measures per patient. We identified few studies (e.g., $8,30,32-37$) that indicated or hinted at their used 375 time unit. As with the estimation level, the used time unit also influences the interpretation and 376 understanding of the DTA estimates 31 . In the previously presented examples, we show that the time 377 unit has a critical implication on the IT's performance; hence, the IT's DTA estimation may be 378 misleading if the time unit does not represent the disease-specific character (e.g., DTA of epilepsy 379 reported with time unit 'days'). Using a short time unit has the advantage to increase precision, as 1380 the number of observations per cluster increases³⁸. Additionally, we recommend being specific in 381 the date and time classification of an episode to ensure an adequate evaluation. If, for example, 382 both tests classify per day (i.e., starting at 00:00 am and finishing at 11:59 pm), then the effect on 383 the DTA estimation, irrespective of time unit and estimation level, would be that the DTA estimates 384 are identical. This is caused by equally inflating the number of observations included in the clusters 385 in comparison to fewer numbers of observations.

386

387 Characteristics of the diagnosis must be considered even before performing the DTA estimation, 388 as they determine the required time unit. The estimation level is somewhat unaffected, but 389 researchers should select a level that best represents the research aim. As shown in the epilepsy 390 example, the sensitivity and specificity estimates of all three estimation levels using 'days' as time 391 unit differed barely. Other diseases which are characterized by medium to long episode periods 392 and medium to long disease-free intervals between episodes, such as $SIRS^{39}$ or depression^{40–42}, 393 could theoretically be assessed using any of the three time units. However, using 'minutes' as time 394 unit significantly increases the number of observations; thus, the evaluation using an estimation 395 tool could be slower due to the large number of observations, while also being more precise. We

396 suggest to only use a small time unit if the aim is to precisely and correctly assess the times of an 397 episode start and end. The translation of observed DTA in a clinically meaningful DTA is often 398 hampered when using small time units as it is inflated when compared to larger time units.

399

400 4.1 Limitations

401 All original datasets were collected with a defined study-specific purpose and modified to some 402 extent (Appendices 4 and 5); thus, they are subject to a certain risk of data-generating pitfalls⁴³. 403 Especially, the depression and epilepsy datasets lacked information on IT and RS diagnoses; hence, 404 IT and RS diagnoses were produced based on the available information in the datasets. 105 Incorporation bias is most likely present in both datasets⁴⁴. However, for this study's purpose it 406 remains unconcerning because we aimed to demonstrate the problem in estimating an IT's DTA 407 using longitudinal data. Note that the simulation of the depression data may likely not reflect a real-408 life situation (i.e., we expected a similar behavior of DTA estimates compared to the other 409 diagnoses).

410 In this study, we assumed that the RSs perfectly diagnosed the diseases. Depending on the clinical 411 setting, this might not be true, especially in situations where the DT is expected to alert clinicians 412 before the RS becomes positive. Researchers should also keep in mind that the IT and/or RS can 413 change over time (e.g., updated guidelines for diagnosis).

414

415 5. Conclusion

416 Using longitudinal data in a DTA study requires researchers to consider methodological choices 417 and a clear pre-defined estimand early in the planning phase. Choices need to be made on the 418 estimation level and the time unit considering diagnostic-specific characteristics as well as the 419 related number of observations included in the DTA estimation. When reporting the DTA study's

- 420 findings, researchers should be transparent and state their rationale for the previously made choices.
- 421 Researchers are not limited to reporting only one estimation level and/or time unit. As a next step,
- 422 these methodological approaches could be improved by using a nonparametric approach that
- 423 incorporates the structured correlation of the time series evaluation as well as other characteristics
- 424 of a real-life dataset (e.g., missing values).

425 LIST OF ABBREVIATIONS

427 DECLARATIONS

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.08.04.23293637;](https://doi.org/10.1101/2023.08.04.23293637) this version posted August 8, 2023. The copyright holder for this

451 https://zivgitlab.uni-muenster.de/ruebsame/dta_longitudinal_data_methods. All rights of the 452 modified-labeled datasets remain with the data owners of this publication. The R package 453 "diagacc" can be accessed via https://github.com/wbr-p/diagacc.

454

455 Acknowledgements

456 We thank Maria Stark (Department of Medical Biometry and Epidemiology, University Medical 457 Center Hamburg, Hamburg, Germany), Jürgen Wellmann (Institute of Epidemiology and Social 458 Medicine, University of Münster, Münster, Germany), and Johannes B. Reitsma (Julius Center for 459 Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, 460 The Netherlands) for their valuable input in understanding and dealing with the challenge of 461 diagnostic test accuracy estimation when using longitudinal data.

462

463 Authors' contributions (CRediT Taxonomy)

464 Julia Böhnke: Conceptualization (equal); data curation (equal); formal analysis (lead); 465 investigation (equal); methodology (lead); project administration (equal); resources (equal); 466 visualization (lead); writing – original draft preparation (lead); writing - review and editing (lead). 467 Antonia Zapf: Conceptualization (equal); data curation (equal); formal analysis (equal); 468 investigation (equal); methodology (equal); project administration (equal); resources (equal); 469 supervision (equal); visualization (equal); writing – original draft preparation (equal); writing – 470 review and editing (equal). Katharina Kramer: Conceptualization (equal); data curation (equal); 471 formal analysis (equal); investigation (equal); methodology (equal); project administration (equal); 472 resources (equal); supervision (equal); visualization (equal); writing – original draft preparation 473 (equal); writing – review and editing (equal). **Philipp Weber:** Writing – analysis program (lead); 474 Writing – review and editing (equal). ELISE Study Group: Writing – review and editing (equal).

475 André Karch: Conceptualization (equal); data curation (equal); formal analysis (equal); 476 investigation (equal); methodology (equal); project administration (equal); resources (equal); 477 supervision (equal); visualization (equal); writing – original draft preparation (equal); writing – 478 review and editing (equal). Nicole Rübsamen: Conceptualization (equal); data curation (equal); 479 formal analysis (equal); investigation (equal); methodology (equal); project administration (equal); 480 resources (equal); supervision (equal); visualization (equal); writing – original draft preparation 481 (equal); writing – review and editing (equal).

482 REFERENCES

- 483 1. Definition of diagnostic test NCI Dictionary of Cancer Terms National Cancer Institute.
- 484 Accessed March 31, 2022. https://www.cancer.gov/publications/dictionaries/cancer-
- 485 terms/def/diagnostic-test
- 486 2. Leeflang MMG, Allerberger F. How to: evaluate a diagnostic test. Clin Microbiol Infect.
- 487 2019;25(1):54-59. doi:10.1016/J.CMI.2018.06.011
- 488 3. European Parliament and Council of the European Union. Regulation (EU) 2017/745 of
- 489 the European Parliament and of the Council of 5 April 2017 on Medical Devices,
- 490 Amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No
- 491 1223/2009 and Repealing Council Directives 90/385/EEC and 93/42/EE.; 2017:1-175.
- 492 Accessed April 5, 2022. https://eur-lex.europa.eu/legal-
- 493 content/EN/TXT/?uri=CELEX%3A32017R0745
- 494 4. Hoyer A, Zapf A. Studies for the evaluation of diagnostic tests:part 28 of a series on
- 495 evaluation of scientific publications. *Dtsch Arztebl Int*. 2021;118(33-34):550-560.
- 496 doi:10.3238/ARZTEBL.M2021.0224
- 497 5. Chassé M, Fergusson DA. Diagnostic Accuracy Studies. Semin Nucl Med. 2019;49(2):87- 498 93. doi:10.1053/J.SEMNUCLMED.2018.11.005
- 499 6. Sitch AJ, Dekkers OM, Scholefield BR, Takwoingi Y. Introduction to diagnostic test 500 accuracy studies. Eur J Endocrinol. 2021;184(2):E5-E9. doi:10.1530/EJE-20-1239
- 501 7. Miller DC, Dunn RL, Wei JT. Assessing the Performance and Validity of Diagnostic Tests
- 502 and Screening Programs. Clin Res Methods Surg. Published online 2006:157-174.
- 503 doi:10.1007/978-1-59745-230-4 10
- 504 8. Böhnke J, Varghese J, Karch A, et al. Systematic review identifies deficiencies in
- 505 reporting of diagnostic test accuracy among clinical decision support systems. J Clin

- 554 01428-7
- 555 24. Wulff A, Mast M, Bode L, Rathert H, Jack T. Towards an Evolutionary Open Pediatric
- 556 Intensive Care Dataset in the ELISE Project. Stud Health Technol Inform. 2022;295.
- 557 doi:10.3233/SHTI220670
- 558 25. Wulff A, Mast M, Bode L, et al. ELISE An open pediatric intensive care data set.
- 559 Published 2022. Accessed August 25, 2022. https://leopard.tu-
- 560 braunschweig.de/receive/dbbs_mods_00070468
- 561 26. Garcia-Ceja E, Riegler M, Jakobsen P, et al. Depresjon: A motor activity database of
- 562 depression episodes in unipolar and bipolar patients. Proc 9th ACM Multimed Syst Conf

563 MMSys 2018. Published online June 12, 2018:472-477. doi:10.1145/3204949.3208125

- 564 27. Shoeb A. Application of Machine Learning to Epileptic Seizure Onset Detection and
- 565 Treatment. Massachusetts Institute of Technology; 2009. Accessed July 19, 2022.
- 566 https://dspace.mit.edu/handle/1721.1/54669
- 567 28. R Core Team. R: A Language and Environment for Statistical Computing. Published 568 online 2021. https://www.r-project.org/
- 569 29. Westwood M, Joore M, Grutters J, et al. Contrast-enhanced ultrasound using SonoVue®
- 570 (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed
- 571 tomography and contrast-enhanced magnetic resonance imaging for the characterisation of
- 572 focal liver lesions and detection of liver met. Health Technol Assess (Rockv).
- 573 2013;17(16):7-243. doi:10.3310/HTA17160
- 574 30. Bode L, Schamer S, Böhnke J, et al. Tracing the Progression of Sepsis in Critically Ill
- 575 Children: Clinical Decision Support for Detection of Hematologic Dysfunction. Appl Clin
- 576 *Inform.* 2022;13(5). doi:10.1055/A-1950-9637
- 577 31. Parsons NR, Teare MD, Sitch AJ. Unit of analysis issues in laboratory-based research.

578 Elife. 2018;7. doi:10.7554/ELIFE.32486

- 579 32. Dewan M, Muthu N, Shelov E, et al. Performance of a Clinical Decision Support Tool to
- 580 Identify PICU Patients at High Risk for Clinical Deterioration. Pediatr Crit Care Med.
- 581 2020;21(2):129-135. doi:10.1097/PCC.0000000000002106
- 582 33. Nagori A, Dhingra LS, Bhatnagar A, Lodha R, Sethi T. Predicting Hemodynamic Shock
- 583 from Thermal Images using Machine Learning. 2019;9(1):1-9. Accessed May 9, 2022.
- 584 https://pubmed.ncbi.nlm.nih.gov/30643187/
- 585 34. Calvert JS, Price DA, Chettipally UK, et al. A computational approach to early sepsis
- 586 detection. Comput Biol Med. 2016;74:69-73. doi:10.1016/J.COMPBIOMED.2016.05.003
- 587 35. Wulff A, Haarbrandt B, Tute E, Marschollek M, Beerbaum P, Jack T. An interoperable
- 588 clinical decision-support system for early detection of SIRS in pediatric intensive care
- 589 using openEHR. Artif Intell Med. 2018;89:10-23. doi:10.1016/J.ARTMED.2018.04.012
- 590 36. Wulff A, Montag S, Steiner B, et al. CADDIE2-evaluation of a clinical decision-support
- 591 system for early detection of systemic inflammatory response syndrome in paediatric
- 592 intensive care: study protocol for a diagnostic study. BMJ Open. 2019;9(6).
- 593 doi:10.1136/BMJOPEN-2019-028953
- 594 37. Wulff A, Montag S, Rübsamen N, et al. Clinical evaluation of an interoperable clinical
- 595 decision-support system for the detection of systemic inflammatory response syndrome in
- 596 critically ill children. BMC Med Inform Decis Mak. 2021;38(1):219-226.
- 597 doi:10.1186/s12911-021-01428-7
- 598 38. Hess AS, Shardell M, Johnson JK, et al. Methods and recommendations for evaluating and
- 599 reporting a new diagnostic test. Eur J Clin Microbiol Infect Dis. 2012;31(9).
- 600 doi:10.1007/S10096-012-1602-1
- 601 39. Chakraborty RK, Burns B. Systemic Inflammatory Response Syndrome. StatPearls.

- 602 Published 2022. Accessed August 17, 2022.
- 603 https://www.ncbi.nlm.nih.gov/books/NBK547669/
- 604 40. Chand SP, Arif H. Depression. StatPearls Publishing; 2022. Accessed November 15, 2022.
- 605 https://www.ncbi.nlm.nih.gov/books/NBK430847/
- 606 41. Goodwin G. Depression. In: Castle D, Coghill D, eds. Comprehensive Men's Mental
- 607 Health. Cambridge University Press; 2021:128-138. doi:10.1017/9781108646765.013
- 608 42. Strunk DR, Pfeifer BJ, Ezawa ID. Depression. In: Wenzel A, ed. Handbook of Cognitive
- 609 Behavioural Therapy: Applications., Vol. 2. American Psychological Association; 2021:3-
- 610 31. doi:http://dx.doi.org/10.1037/0000219-001
- 611 43. Morris TP, White IR, Crowther MJ. Using simulation studies to evaluate statistical
- 612 methods. Stat Med. 2019;38(11):2074-2102. doi:10.1002/SIM.8086
- 613 44. Catalogue of Bias Collaboration. Incorporation bias. In: Plüddemann A, McCall M, eds.
- 614 Scakett Catalogue of Biases 2019. ; 2019. Accessed November 21, 2022.
- 615 https://catalogofbias.org/biases/incorporation-bias/
- 616

617 ONLINE SUPPLEMENTARY MATERIALS

- 619 Appendix 1 Key terminology of diagnostic test accuracy and diagnostic test accuracy studies
- 620 Appendix 2 Repeated test application in a longitudinal setting
- 621 Appendix 3 STARD 2015 checklist
- 622 Appendix 4 Labeling approaches per estimation level
- 623 Appendix 5 Dataset modifications and results of different labeling and correction approaches
- 624 Appendix 6 Flow chart per dataset
- 625 Appendix 7 Demographic characteristics of participants per modified diagnostic dataset